There is no evidence that propranolol affects fertility in men or women. Abirateron: (moderate) Monitor blood pressure and heart rate if simultaneous administration of propranolol and abiraterone is required. Propranolol is a CYP2D6 substrate and abiraterone is a CYP2D6 inhibitor. Concomitant use may lead to hypotension and bradycardia. Paracetamol; aspirin, ASA; Caffeine: (moderate) Simultaneous use of beta-blockers with aspirin and other salicylates may lead to loss of hypotensive activity due to inhibition of renal prostaglandins and thus salt and water retention and decreased renal blood flow. Paracetamol; Aspirin: (moderate) Concomitant use of beta-blockers with aspirin and other salicylates may lead to loss of antihypertensive activity due to inhibition of renal prostaglandins, and thus salt and water retention and decreased renal blood flow. Paracetamol; Aspirin; Diphenhydramine: (moderate) The simultaneous use of beta-blockers with aspirin and other salicylates may lead to loss of hypotensive activity due to inhibition of renal prostaglandins and thus salt and water retention and decreased renal blood flow. Paracetamol; Caffeine; magnesium salicylate; Phenyltoloxamine: (moderate) The simultaneous use of beta-blockers with aspirin and other salicylates may lead to loss of hypotensive activity due to inhibition of renal prostaglandins, and thus salt and water retention and decreased renal blood flow. Paracetamol; Caffeine; phenyltoloxamine; Salicylamide: (moderate) The simultaneous use of beta-blockers with aspirin and other salicylates may lead to a loss of hypotensive activity due to inhibition of renal prostaglandins and thus salt and water retention and decreased renal blood flow. Paracetamol; Propoxyphene: Propranolol (minor) is significantly metabolized by CYP2D6 isoenzymes and CYP2D6 inhibitors such as propoxyphene could theoretically alter propranolol metabolism; The clinical significance of such interactions is unknown. Adenosine: (Moderate) Use adenosine with caution in the presence of beta-blockers because of the potential for additive or synergistic depressant effects on sinoatrial and atrioventricular lymph nodes. Alligurid: (moderate) Increased frequency of blood glucose monitoring may be required when a beta-blocker with antidiabetic agents is administered.
Because beta-blockers inhibit the release of catecholamines, these drugs can hide symptoms of hypoglycemia such as tremors, tachycardia, and blood pressure changes. Other symptoms such as headache, dizziness, nervousness, mood swings or hunger are not alleviated. Beta-blockers also exert complex effects on the body`s ability to regulate blood sugar. Some beta-blockers, particularly non-selective beta-blockers such as propranolol, have been found to increase insulin-induced hypoglycemia and a delay in restoring blood sugar to normal levels. Hyperglycemia has also been reported and may be due to blockade of beta-2 receptors in the beta cells of the pancreas. A selective beta-blocker may be preferred in patients with diabetes mellitus if it is appropriate for the patient`s condition. Selective beta-blockers such as atenolol or metoprolol do not appear to potentiate insulin-induced hypoglycaemia. Although beta-blockers may have negative effects on glycaemic control, they reduce the risk of cardiovascular disease and stroke in diabetic patients and their use should not be avoided in patients with convincing indications for beta-blocker treatment if there are no other contraindications. Aldesleukin, IL-2: Beta-blockers (moderate) may potentiate the hypotension seen in aldesleukin, IL2.
Alemtuzumab: (moderate) Alemtuzumab may cause hypotension. Careful monitoring of blood pressure and antihypertensive symptoms is recommended, especially in patients with ischemic heart disease and in patients on antihypertensive drugs. Alfentanil: (moderate) Alfentanil can cause bradycardia. The risk of significant hypotension and/or bradycardia during treatment with alfentanil is increased in patients receiving beta-blockers. Alfuzosin: (moderate) The manufacturer warns that combining alfuzosin with antihypertensive agents may cause hypotension in some patients. Alfuzosin (2.5 mg, immediate) potentiated the hypotensive effect of atenolol (100 mg) in eight healthy young male volunteers. Alfuzosin Cmax and AUC were increased by 28% and 21%, respectively. Alfuzosin increased atenolol Cmax and AUC by 26% and 14%, respectively. Significant reductions in mean blood pressure and mean heart rate have been reported with the combination.
Aliskiren; Amlodipine: (moderate) Co-administration of amlodipine and beta-blockers may reduce angina pectoris and improve exercise tolerance. However, when these drugs are administered together, hypotension and impaired cardiac output may occur, especially in patients with left ventricular dysfunction, cardiac arrhythmias or aortic stenosis. Aliskiren; amlodipine; Hydrochlorothiazide, HCTZ: (moderate) Co-administration of amlodipine and beta-blockers may reduce angina pectoris and improve exercise tolerance. However, when these drugs are administered together, hypotension and impaired cardiac output may occur, especially in patients with left ventricular dysfunction, cardiac arrhythmias or aortic stenosis. alogliptin; Metformin: (moderate) Increased frequency of blood glucose monitoring may be required when a beta-blocker with antidiabetic agents is administered. Because beta-blockers inhibit the release of catecholamines, these drugs can hide symptoms of hypoglycemia such as tremors, tachycardia, and blood pressure changes. Other symptoms such as headache, dizziness, nervousness, mood swings or hunger are not alleviated. Beta-blockers also exert complex effects on the body`s ability to regulate blood sugar. Some beta-blockers, particularly non-selective beta-blockers such as propranolol, have been found to increase insulin-induced hypoglycemia and a delay in restoring blood sugar to normal levels. Hyperglycemia has also been reported and may be due to blockade of beta-2 receptors in the beta cells of the pancreas. A selective beta-blocker may be preferred in patients with diabetes mellitus if it is appropriate for the patient`s condition. Selective beta-blockers such as atenolol or metoprolol do not appear to potentiate insulin-induced hypoglycaemia.
Although beta-blockers may have negative effects on glycaemic control, they reduce the risk of cardiovascular disease and stroke in diabetic patients and their use should not be avoided in patients with convincing indications for beta-blocker treatment if there are no other contraindications. Alpha-blockers: (moderate) Orthostatic hypotension may be more likely when beta-blockers are administered at the same time as alpha-blockers. Alpha glucosidase inhibitors: (moderate) Increased frequency of blood glucose monitoring may be required when a beta-blocker with antidiabetic agents is administered. Because beta-blockers inhibit the release of catecholamines, these drugs can hide symptoms of hypoglycemia such as tremors, tachycardia, and blood pressure changes.
Comments are closed.